RT @BCD_AACR: Scientific Editor and published author at Blood Cancer Discovery, Catherine J. Wu, now presenting on “Human genetic studies:…
RT @BCD_AACR: Scientific Editor and published author at Blood Cancer Discovery, Catherine J. Wu, now presenting on “Human genetic studies:…
Scientific Editor and published author at Blood Cancer Discovery, Catherine J. Wu, now presenting on “Human genetic studies: CLL and transformation,” at #AACRlymph22. https://t.co/5TTWtlhiPS
Methylation in CLL https://t.co/00HuJs5veW
Blood Cancer Discovery Scientific Editor Catherine Wu opens #HMSRC21 with a keynote talk on #CLL heterogeneity. Read her related article: https://t.co/Cuhfip99xF #leusm https://t.co/gA1CTn12EV
New article: Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy https://t.co/JvoBRf40iC #CLL #leusm #hematology
RT @CeMM_papers: Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy https://t.co/ZKuFvD…
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy https://t.co/ZKuFvDS82U
RT @BCD_AACR: ICYMI: Pre-neoplastic alterations define CLL DNA methylome and persist through disease progression and therapy. https://t.co/…
ICYMI: Pre-neoplastic alterations define CLL DNA methylome and persist through disease progression and therapy. https://t.co/bTfUiBdSi0 Read the related commentary: Epigenetic Trajectories of the Premalignant-to-Malignant Transition of CLL. https://t.co/s2
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy https://t.co/jM6nUBXpHd
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy https://t.co/iuOk0A7mFg https://t.co/nJnp2XKPTO
Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. https://t.co/2DDEzDPlfK https://t.co/ZAR9oPYClb
New article: Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. https://t.co/Cs8Zsq4rz6 #CLL #leusm #hematology
RT @BCD_AACR: ICYMI: Pre-neoplastic alterations define CLL DNA methylome and persist through disease progression and therapy. https://t.co/…
RT @BCD_AACR: ICYMI: Pre-neoplastic alterations define CLL DNA methylome and persist through disease progression and therapy. https://t.co/…
ICYMI: Pre-neoplastic alterations define CLL DNA methylome and persist through disease progression and therapy. https://t.co/6HEI4eHTSo Read the related commentary: Epigenetic Trajectories of the Premalignant-to-Malignant Transition of CLL. https://t.co/KB
ICYMI: Pre-neoplastic alterations define CLL DNA methylome and persist through disease progression and therapy. https://t.co/Tnlem8nHPD Read the related commentary: Epigenetic Trajectories of the Premalignant-to-Malignant Transition of CLL. https://t.co/PK
RT @TeifLab: An interesting study comparing the methylome (RRBS) of CLL and pre-CLL B cells (precancerous stage), published by the groups…
RT @TeifLab: An interesting study comparing the methylome (RRBS) of CLL and pre-CLL B cells (precancerous stage), published by the groups…
An interesting study comparing the methylome (RRBS) of CLL and pre-CLL B cells (precancerous stage), published by the groups of Alexander Meissner and Catherine Wu https://t.co/BzxQnlDJVp. Have a look @KarstenRippe, @kostareli @CharlotteAurora @Babis_xant
Pre-neoplastic alterations define #CLL DNA methylome and persist through disease progression and therapy. https://t.co/VN4fEcYCLj Commentary: Epigenetic Trajectories of the Premalignant-to-Malignant Transition of Chronic Lymphocytic Leukemia. https://t
Ahead of Print: Pre-neoplastic alterations define #CLL DNA methylome and persist through disease progression and therapy. @MPI_MolGen @DanaFarberNews @VHIO @broadinstitute @MayoClinic @helenekretzmer #leusm https://t.co/paX70V3bBI https://t.co/bZmUO9FkRg